GlaxoSmithKline provides update on divestment of non-core over-the-counter (OTC) brands
- Details
- Category: GlaxoSmithKline
GSK has reached agreement to divest the previously identified non-core OTC brands in the United States and Canada to Prestige Brands Holdings, Inc. for £426 million ($660 million) in cash.
AstraZeneca updates on olaparib and TC-5214 development programmes
- Details
- Category: AstraZeneca
AstraZeneca announced that its investigational compound olaparib will not progress into Phase III development for the maintenance treatment of serous ovarian cancer. In addition, AstraZeneca announced that the second RENAISSANCE Phase III study of TC-5214 for patients with major depressive disorder did not meet its primary end point.
Four potential blockbusters in the Pharma pipeline
- Details
- Category: Bayer
The Bayer Group plans to continue investing heavily in research and development and expects its Pharmaceuticals business in particular to generate substantial sales with the new products that are scheduled to be launched in the next 18 months.
Amgen and Watson Announce Collaboration to Develop and Commercialize Oncology Biosimilars
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) and Watson Pharmaceuticals, Inc. (NYSE:WPI) announced that they will collaborate to develop and commercialize, on a worldwide basis, several oncology antibody biosimilar medicines.
Prevent Pneumococcal Disease in Infants and Young Children in the World's Poorest Countries
- Details
- Category: Pfizer
Pfizer Inc. (NYSE:PFE) has entered into a second supply agreement which will broaden and extend the duration of the Company's commitment to help protect millions of infants and young children in the developing world from pneumococcal disease - the leading cause of vaccine-preventable death in young children.
Simcere and Bristol-Myers Squibb Enter Innovative Partnership
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) and Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company in China, have expanded the strategic partnership formed last year to include a second collaboration in a different therapeutic area.
Deeper levels of response with Tasigna® compared to Glivec®
- Details
- Category: Novartis
Phase III clinical trial data contribute to the growing evidence that adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase who are treated with Tasigna® (nilotinib) have deeper levels of response compared to those treated with Glivec® (imatinib)*[1],[2].
More Pharma News ...
- Merck Helps Eliminate Schistosomiasis in Africa
- Abbott and Reata Pharmaceuticals Announce Agreement
- Pfizer Elects CEO Ian Read as Chairman of the Board
- Most couples prefer spontaneity in the bedroom
- Afinitor® significantly extends time women with advanced breast cancer live without tumor growth
- AstraZeneca to acquire generics company to broaden patient access to medicines in China
- AstraZeneca to streamline US sales organisation